Annovis Bio Inc (ANVS)
NYSE:ANVS
Top Page
Annovis Bio
(NYSE:ANVS)
Select Model
Select Model
Rating:45Neutral
Price Target:
$2.00
▼(-11.89% Downside)
Action:ReiteratedDate:03/14/26
The score is primarily constrained by weak financial performance (no revenue, escalating losses, and persistent cash burn), implying continued reliance on external funding. Technicals are modestly negative with price below key moving averages and a negative MACD. A positive Phase 3 safety update provides some support, but the long runway to efficacy data and lack of meaningful valuation anchors (negative P/E, no dividend) keep the overall score low.
Positive Factors
Phase 3 safety de-risking
An independent DSMB's positive six-month safety recommendation materially reduces regulatory and execution risk for buntanetap's pivotal Alzheimer’s trial. Alignment of safety across Alzheimer’s and Parkinson’s programs and possible combined safety data for an NDA are durable de-risking factors supporting continued enrollment and regulatory dialogue.
Negative Factors
Persistent cash burn
Consistent negative operating and free cash flow, with material worsening recently, indicates the company cannot self-fund development and will remain dependent on external financing. That structural cash burn elevates dilution and execution risk and constrains strategic optionality until revenue or sustained funding emerges.
Read all positive and negative factors
Positive Factors
Negative Factors
Phase 3 safety de-risking
An independent DSMB's positive six-month safety recommendation materially reduces regulatory and execution risk for buntanetap's pivotal Alzheimer’s trial. Alignment of safety across Alzheimer’s and Parkinson’s programs and possible combined safety data for an NDA are durable de-risking factors supporting continued enrollment and regulatory dialogue.
Read all positive factors
Annovis Bio (ANVS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$64.37M
Dividend YieldN/A
Average Volume (3M)468.73K
Price to Earnings (P/E)―
Beta (1Y)3.24
Revenue GrowthN/A
EPS Growth62.84%
CountryUS
Employees8
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.39
Shares Outstanding28,355,263
10 Day Avg. Volume564,611
30 Day Avg. Volume468,733
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)4.22
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap-302.75
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda660.07
Forecast
1Y Price Target
$12.50Price Target Upside450.66% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.1
Revenue Forecast (FY)N/A
Annovis Bio Business Overview & Revenue Model
Company Description
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheim...
How the Company Makes Money
null...
Annovis Bio Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
40
Negative
Cash Flow
6
Very Negative
| Breakdown | Dec 2025 | Mar 2025 | Mar 2024 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -29.70M | -26.69M | -45.03M | -25.51M | -14.50M |
| Net Income | -28.85M | -24.59M | -56.20M | -25.33M | -14.49M |
Balance Sheet | |||||
| Total Assets | 21.08M | 13.93M | 10.21M | 36.02M | 46.00M |
| Cash, Cash Equivalents and Short-Term Investments | 19.53B | 10.55M | 5.75M | 28.38M | 45.69M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 4.23M | 4.62M | 17.96M | 7.70M | 1.51M |
| Stockholders Equity | 16.85M | 9.31M | -7.75M | 28.32M | 44.49M |
Cash Flow | |||||
| Free Cash Flow | -25.62B | -21.89B | -39.97M | -17.31M | -9.13M |
| Operating Cash Flow | -25.62B | -21.89B | -39.97M | -17.31M | -9.13M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 34.60B | 26.69B | 17.34M | 4.61K | 46.74M |
Annovis Bio Technical Analysis
Negative
2.27
Price Trends
2.50
Negative
3.10
Negative
2.73
Negative
Market Momentum
-0.10
Negative
46.42
Neutral
42.80
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ANVS, the sentiment is Negative. The current price of 2.27 is below the 20-day moving average (MA) of 2.38, below the 50-day MA of 2.50, and below the 200-day MA of 2.73, indicating a bearish trend. The MACD of -0.10 indicates Negative momentum. The RSI at 46.42 is Neutral, neither overbought nor oversold. The STOCH value of 42.80 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ANVS.
Annovis Bio Risk Analysis
Annovis Bio disclosed 77 risk factors in its most recent earnings report. Annovis Bio reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Annovis Bio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $154.79M | ― | -96.96% | ― | -99.07% | -10347.56% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $161.88M | -7.27 | -10.35% | ― | -42.62% | ― | |
51 Neutral | $93.59M | -4.25 | -62.18% | ― | -58.26% | -53.20% | |
45 Neutral | $64.37M | ― | -159.43% | ― | ― | 62.84% | |
45 Neutral | $189.92M | -1.27 | -97.41% | ― | ― | -60.99% |
* Healthcare Sector Average
ANVS
Annovis Bio
2.30
1.01
78.29%
WHWK
Whitehawk Therapeutics
3.41
1.76
106.67%
DTIL
Precision BioSciences
5.99
1.44
31.65%
GLSI
Greenwich LifeSciences
24.20
14.77
156.63%
ABOS
Acumen Pharmaceuticals
2.58
1.52
143.40%
COYA
Coya Therapeutics, Inc.
4.11
-1.13
-21.56%
Annovis Bio Corporate Events
Business Operations and StrategyRegulatory Filings and Compliance
Annovis Bio Advances Alzheimer’s Phase 3 Trial After Safety Nod
Positive
Feb 12, 2026
On February 12, 2026, Annovis Bio said an independent Data and Safety Monitoring Board issued a positive safety recommendation at six months for its pivotal Phase 3 Alzheimer’s trial of buntanetap, allowing the U.S. study to continue without...
Business Operations and StrategyRegulatory Filings and Compliance
Annovis Bio Hosts Regulation FD Investor Information Webinar
Neutral
Jan 28, 2026
On January 28, 2026, Annovis Bio, Inc. held a webinar, supported by a prepared presentation that was made available to participants and stakeholders. The event signaled an effort by the company to formally communicate information to the market via...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.